Cargando…
Advances in Combination Therapy for Asthma and COPD.
Aimed at specialists in respiratory medicine, this new book comprehensively reviews the variety of agents currently available for treatment of asthma, COPD, and other airway diseases and covers practical guidelines as well as challenges and complications in their use. Advances in Combination Therapy...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Hoboken :
John Wiley & Sons,
2011.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- ADVANCES IN COMBINATIONTHERAPY FOR ASTHMAAND COPD; Contents; Contributors; Preface; 1 Similarities and differences in the pathophysiology of asthma and COPD; 1.1 Introduction; 1.2 Pulmonary function abnormalities in asthma and COPD; 1.3 Risk factors for asthma and COPD; 1.4 Cellular inflammation in asthma and COPD; 1.5 Distribution and consequences of inflammation in asthma and COPD; 1.6 Patterns of epithelial injury in asthma and COPD; 1.7 Airway hyperresponsiveness; 1.8 Beta-receptor blockers; 1.9 Differential diagnosis of asthma and COPD; 1.10 Overlap syndrome; 1.11 Conclusion; References.
- 2 Glucocorticoids: pharmacology and mechanisms2.1 Introduction; 2.2 Chemical structures; 2.3 The molecular basis of inflammation; 2.4 Cellular effects of glucocorticoids; 2.5 Glucocorticoid receptors; 2.6 Glucocorticoid activation of gene transcription; 2.7 Suppression of inflammatory genes; 2.8 Steroid resistance; 2.9 Interaction with ß2-adrenergic receptors; 2.10 Conclusions; References; 3 Inhaled corticosteroids: clinical effects in asthma and COPD; 3.1 Introduction; 3.2 Anti-inflammatory activity of corticosteroids; 3.3 Routes of administration; 3.4 Absorption and fate of corticosteroids.
- 3.5 Currently available inhaled corticosteroids3.6 Efficacy in asthma; 3.7 Efficacy in COPD; 3.8 Side effects of ICS; 3.9 Conclusions; References; 4 LABAs: pharmacology, mechanisms and interaction with anti-inflammatory treatments; 4.1 Galenical forms of LABAs: formulations, isomers, enantiomers, diasteriomers and salts; 4.2 Absolute and functional ß2-adrenoceptor selectivity; 4.3 Cellular organization of receptor clusters: functional structure of the ß2-adrenoceptor and mode of signalling; 4.4 Dimers and oligomers: homo- and heterodimerism/oligoism.
- 4.5 Pharmacogenomics of the ß2-adrenoceptor and adenylate cyclase polymorphism in relation to LABAs4.6 Understanding the 'reassertion' paradox, 'exosites' and relative speed of onset: the membrane diffusion microkinetic model of LABA action; 4.7 Regulation and desensitization; 4.8 Full versus partial agonism (pharmacological efficacy); 4.9 Beta-blockers not LABAs?; 4.10 Non-receptor-mediated effects?; 4.11 Biochemical basis of functional antagonism and its critical role in LABA action in disease and exacerbations; 4.12 Molecular cooperativity between LABAs and steroids; 4.13 Perspective.